LGALS3 and hepatocellular carcinoma: A study indicated that serum galectin-3 levels in CHB patients were decreased compared with those in patients with hepatocellular carcinoma and cirrhosis and confirmed that there was no difference in serum galectin-3 levels between patients with hepatocellular carcinoma and patients with cirrhosis [38, 39].